Macrogenics Inc. (M55)
XSTU 
Summary
M55 Chart
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead
Positive risk/reward with MacroGenics trading at a discount to its $327 million cash position or $5.15/share. Differentiated pipeline includes antibody drug conjugates (ADC), T-cell engagers (TCE), and lorigerlimab, with multiple near-term catalysts to drive potential upside. Gilead's recent activity on multiple TCEs and MacroGenics' negative enterprise value suggest partnership is under appreciated & undervalued.
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Here is how MacroGenics (MGNX) and CareDx (CDNA) have performed compared to their sector so far this year.
Macrogenics Inc. (M55) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Macrogenics Inc. ever had a stock split?
Macrogenics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Eric Risser CEO | XSTU Exchange | 556099109 CUSIP |
| US Country | 293 Employees | - Last Dividend | - Last Split | 10 Oct 2013 IPO Date |
Overview
MacroGenics, Inc. is a seasoned biopharmaceutical entity based in Rockville, Maryland, United States, that specializes in discovering, developing, and bringing to market antibody-based therapeutics aimed at combating cancer. Since its inception in 2000, MacroGenics has focused on employing its proprietary technology to create novel treatments that offer hope to patients battling various cancer types. With a strong commitment to innovation and excellence, MacroGenics has established collaborations with notable industry players such as Incyte Corporation, Zai Lab Limited, I-Mab Biopharma, and Janssen Biotech, Inc., furthering its reach and impact within the biopharmaceutical field.
Products and Services
- MARGENZA (margetuximab-cmkb)
- Immuno-Oncology Product Candidates
- MGC018: An antibody-drug conjugate (ADC) targeting solid tumors expressing B7-H3.
- Enoblituzumab: A monoclonal antibody targeting B7-H3 to treat cancer.
- MGD024: A bispecific CD123 × CD3 DART (Dual-Affinity Re-Targeting) molecule designed to minimize cytokine-release syndrome for patients with hematologic malignancies.
- Other Therapeutic Candidates
- Lorigerlimab: A monoclonal antibody targeting PD-1 and CTLA-4 immune checkpoints.
- Tebotelimab: A tetravalent DART molecule for PD-1 and LAG-3.
- Retifanlimab: A programmed death receptor-1 (PD-1) targeting humanized monoclonal antibody.
- IMGC936: An ADC targeting ADAM9, a cell surface protein overexpressed in various solid tumor types.
- MGD014 and MGD020: DART molecules targeting human immunodeficiency virus (HIV) infected cells and CD3 on T cells.
- Teplizumab: Under development for treating type 1 diabetes.
- PRV-3279: A CD32B × CD79B DART molecule aimed at treating autoimmune diseases.
This product is an approved human epidermal growth factor receptor 2 (HER2) receptor antagonist, used in combination with chemotherapy, for treating adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens. MARGENZA represents a significant advancement in the treatment of this challenging cancer type, offering new hope to patients who have exhausted other therapeutic options.
MacroGenics' pipeline comprises several promising immuno-oncology product candidates in various development stages:
Beyond cancer treatment, MacroGenics is developing therapies targeting autoimmune diseases and infectious diseases, including:
Contact Information
